Trifluridine–tipiracil (Lonsurf, Servier Laboratories) plus bevacizumab is indicated for 'the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents'.
The dosage schedules are available in the summary of product characteristics for trifluridine–tipiracil and the summary of product characteristics for bevacizumab.
The list price of trifluridine–tipiracil (15 mg/6.14 mg) is £500.00 per 20‑tablet pack and £1,500.00 per 60‑tablet pack (excluding VAT; BNF online accessed July 2024). The list price of trifluridine–tipiracil (20 mg/8.19 mg) is £666.67 per 20‑tablet pack and £2,000.00 per 60‑tablet pack (excluding VAT; BNF online accessed July 2024).
The list price of bevacizumab (25 mg/ml) varies between £205.55 and £242.66 per 4‑ml vial, and between £810.10 and £924.40 per 16‑ml vial (excluding VAT; BNF online accessed July 2024).
The company has a commercial arrangement. This makes trifluridine–tipiracil available to the NHS with a discount. The size of the discount is commercial in confidence.
There is a discount for bevacizumab agreed with the Medicines Procurement and Supply Chain. The prices agreed through the framework are commercial in confidence.